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AE lnany as one quarter of patients treated with thrombolylic 
therapy praent with cungestive heart Failure or cardiogenic 
shuck. Afthough thrmttbulytic therapy has hewt shown to limit 
i&ret sire, preserve lelt ventricular ejectian fraction and de. 
crease mortality in most subgroups of patients, no apparent 
benefit has been demonstrated in patients with clinical left veu- 
triculnr dysfunction. The lack of correlation between ejection 
fract:an and other measurements of kh ventricular dysfunction 
such as exe&e time, cardiac output, fill@ pressures, activation 
af the neuruhumoral system and regional perfusion bed abuor- 
malilies may partly explain this paradox. Alternatively, lower 
perfuahnt rates, higher reocchtsion rates. associated mechanical 
complicatioas uc completed infarction muy explain these findings. 
Preliminary dab indicate that emergency coronary %gio- 
Several controlled trials I l-5) of intravenous thrombolysis in 
acute myocardial infarction have venfied the important 
lifesaving potential of this therapy. Although overall benefit 
has consistently been shown. certain subgroups of patients 
have had equivocal results. Whereas elderly patients dem- 
onstrate apparent mortality reduction from reperfur,ion ther- 
apy (l-4) and data are supportive for treating patienls with 
late presentation (3.9, inferior myocardial infarction IZ-4. 
hypertension (3). previous myocardial infarction (3.6). lim- 
ited cardiopulmonary resuscitation (7) and new bundle 
branch block (31, patients with ST segment depression have 
not shown survival benefit tl,3). Until additional evidence 
suggests differently. most investtgarors (8.91 recommend 
withholding therapv in this subgroup. although other: I IO) 
suggest that the limitations of subset analysis explain the 
lack of benefit and thus al! palients with presumed myocar- 
dial infarction should be treated. 
Cutiously missing from previous reports regarding subset 
xtalyses are the results of thrombolyric therapy in pafients 
with congestive heart failure and cardiogenic shock. In this 
review, we summarize the available repcrfusion trial data for 
this important subgroup of patients who prwnt fur Ireal- 
plartg DT bypax grafl surgery improves suryivat in selected 
patients nith cardiogenic shuck. Because these findings suggest 
lhat reslorstian of infarct artery patency is especially important in 
patients with clinical left ventricular dysfunction, additional stud- 
ies are needed in there patieuls to investigate the potential benelit 
that new lhrambulylic stra;egies, inntropic or vasedilator apenS 
or intraaartic ballooncounlerpukation might Mier by augmenting 
curouary bloud Ooa aud improving reperkion rater. Currently, 
acute mechsnical revuswlarizatiun should be coonsidered for pa- 
tients who preseet with cungeslire heart faihxe associated with 
hypatension or tachycardia and fur patients with cardiogenic 
shuck. 
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mettt wtth left vcntrtcular decompen~tiatt and recommend a 
managcmcnt approach. 
Congestive Heart Failare 
Risk stratificaliin. Killip and Kimball III) initially dc- 
scribed the progressive inguencc of congestive heart failure. 
pulmonary edemnand cardiogenic shock on the incidence of 
death in 250 consecutive patients with myocardial infarction 
treated in a coronary care unit setting (Table It. Thus scheme 
of risk stratification remains clinically useful today. In fact. 
IWO major thmmbolytic trials (1.12.13t have used this clas- 
sification in reporting results. Table Z shows that almost 25% 
of patients enrolled in the% lrials had congestive heart 
failure IKillip class II) or pulmonary edema (Killip class III) 
at prcscntation. Unfortunutsly. it doer not appear that a 
clinically important survival benefit was achieved with 
thrombolytic therapy III or thrombolytic therapy plus arpi- 
rin(l1.13) compared ffith placebo(Table 3)oreven with the 
initial experience of Killip and Kimball (Table II (I IL The 
findiug that 2% of patients in Killip class If and 5WE of 
those in Killio class 111 were dead at I vear in the Gruuao 
It&no per lo Studio della Strepiochi&i nell’lnfarto &- 
cardico(CISSI-II trial (14)tTable 3) ira soberingcontrast to 
the excellent survival rates reported for treating relatively 
low risk patients in the Thrombolysis m Myocardial tnfarc- 
tton ITIMII-II trial (15) and is sotttcwhat surprising given the 
documented benefit of thrombolytic therapy in dccrcasing 
infarct size and preserving left ventricular ejection fraction. 
Table 1. Ho&d Mortality Kale Accordmg to Kdlip Class* 
NO. of Monaliry 
Infarct size. In a dog model, Reimer et al. (16) demon- 
strated that myocardial Inecrosis occurs over several hours 
aner arteridl occlusion. spreading in a wave front from 
endocardium to epicxdium. and that reperfusion within 3 h 
could abort the process and preserve an epicardial rim of 
viable tissue Using release of the enzyme hydroxybutyric 
dehydrogenase as a measure of infarct size. Simoons el al. 
(17) reported a remarkably similar result in humans, obscrv- 
ing that intracoronary streptokmase reduced infarct size 
compared with that achieved with placebo when treatment 
was given within 3 h. Although, in humans, the lime of total 
arterial occlusion can be difficult to determine, intermittent 
patency can occur and collateral circulation should preserve 
cell viability, no reduction in infarct size was seen in patients 
with z-3 h of symptoms (17). A reduction in enzyme release 
in treated patients was also shown in the intravenous Strep- 
tokinaae in Acute Myocardial Infarction (NAM) trial (IS) 
and the fifth European Cooperative Study Group trial (19). 
However, no change in infarct size as measured by a nuclear 
imaging technique was found in treated patients in the 
Western Wa*..ngton intracoronaty slreptokinase trial (201, 
where time to treatment averaged 4.7 h. The importance of 
decreasing infarct size by early reperfusion is illustrated by 
the fact that the greatest reduction in mortality occurs in 
patients treated within I h of symptom onset (1,31. Also, 
patients with the largest ischemic areas. the patients most 
likely to develop congestive heart failure, appear to have the 
greatest reduction in infarct size with treatment [2l,22). 
Left ventricular ejection fraction. Left ventricular ejec- 
tion fraction is a strong predictor of death in patients with 
coronary artery disease (23). Whereas it was expected that a 
reduction in infarct size with tbrombolytic therapy could 
preserve acute lefl ventricular ejeclinc fraction and thus 
Table 2. Kitlip Class aI Entry in Two Trials 
reduce mortality, it was surprising to find Ihat lale (24) or 
even delayed spontaneous (25) reperfusion in untreated 
patients could also improve ejection fraction and that late 
trealment could decrease mortality (3). Thus, it appears that 
arterial patency has a beneficial effect on left ventricular 
ejection fraction and mortality independent from myocardial 
salvage (26). It has been suggested (26) that restoration of 
coronary blood Row improves healing and decreases infarct 
expansion and left ventricular dilation after myocardial 
infarction. The reduction in end-systolic volume (271, mural 
thrombus formation and electrical instability (28) associated 
with arterial patency is a possible explanation for improved 
survival in patients without infarct size reduction. 
The importance of successful thrombolysis in decreasing 
mortality in patients with a reduced ejection fraction was 
first shown in the Western Washiugton intracoronary strep 
tokinase trial (29.30) (Fig. I). Additionally, the greatest 
recovery of ejection fraction percentage points due to early 
thrombolysis has been found in patients with the lowest 
entry ejection fraction, the patients most likely to develop 
congestive hear1 failure, with little improvement possible in 
patients with a normal e&lion fraction (31). The reported 
relatively small difference in mean ejeclion fraction between 
treated and control patients (5 to 8 percentage points) partly 
reflects the fact that 70% to 80% of patients witi] myocardial 
infarction and ST segment elevation have not previously had 
myacardial infarction (t-3). 66% may have one-vessel dis- 
ease (32) and average left ventricular ejection fraction in 
survivors is 50% to 55% 133). 
Thrombolytic therapy. Congestive heart failure is a clin- 
ical syndrome that is variably defined by physical signs, 
radiographic findings or medication profiles and therefore 
may be more difficult to accurately measure than infarct size 
or left ventricular ejection fraction. The distribution of Killip 
class at entry in the two large trials (I .IZ.f3) with squivalent 
entry criteria (Table 2J was similar, with a r,liihtly lower 
incidence of patients in Killip classes It to IV in the 
lnternaiional trial (12.13) probably reflecting a shorter treat- 
ment window (6 h) than was used in GISSI-I (12 h)(l). It is 
important when interpreting published findings to determine 
whether Killip class was documented at presentation to the 
hospital or whether it was noted during the course of 
hospiralization after Itealment. Results from several trials 
Kiltip II 
1x2 ,X1] 
IJ4U I22 41 
Kiltip 111 Killip tV 
1~1 I,.?, ,ils ,2.5, 
246,4_?, 134 12.31 
Table 3. bhtalily Rates by Kilhp Ciasr 
(4,6,17.34-38) show the incidence ofcongertwe hwn failure 
during the hospital course to vary widely (Table 4). Sample 
size, referral bias, entry criteria or thoroughness ol data 
collection may explain some of the differences. Although not 
consistently found. there appears to be u lower incidence of 
congestive hext failure during hospitalization in treated 
compared with control patients (Table 4). Thus. whereas 
thromholytic therapy may not dramatically decrease the high 
mortality rate in patients who present with congestive hean 
failure (Table 3). it may decrease the later development of 
congestive heart failure in patients who undergo successful 
reperfusion. 
The potential ability of thrombolytic therapy to improve 
survival in patients with a low ejection fraction compared 
with poor results in those with congeslive heart failure 
should not seem too perplexing. Previous studies (39.40) 
have demonstrated that ejection fraction is not related to 
other rneasuremenis of left ventricular function. such as 
exercise time. cardiac output and filling pressure. Morecver. 
the clinical syndrome ofcongestive heart failure is a complex 
multisystem disorder that can involve abnormalities of the 
neurohumoral system and regional perfusion beds. The 
Eigure 1. Rela!ion between left ventricular ejection fraction at 
admission and I-year survival riles in the Werlem Washington 
intracaronary slreptokinase lnal (291 by uealmcnr s~mwgy and 
repelfusion slatu~ Reproduced from Stadiur (3~. with permission. 
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r;iilure of thrombolytic therapy to dramatically decrease 
mc&;~ ;II pOXiii5 WLIV piikmtt nZ wdg~~lW2 ilean 
failure could be ew’ained by physiologically more signifi- 
cant left wntricular dysfunction, Lower reperfusion rates. 
moG_ :d mechanical complications (mitral regurgitation. 
vemncular septal defect. nyocardial rupture) or completed 
infarction Baseline left ventricular qection reaction before 
myocardial infarction may not be critically related because 
survival benefit was shown in treated patients with prior 
myocardial infarction in both the ISIS-2 (3) and APSAC 
Intervention Mortality Study IAIMS) (6) Irials. 
Left ventricular ejection ftwtion: mortalfly paradox. Van 
de Werf 141) noted that although placebo-controlled trials 
have demonstra!ed either significant improvemenr in left 
venrricular ejection fraction or significant reduction in mar- 
rality. no smgie study has shown improvement in both end 
poinis. This is paradoxic because the greatest mortality 
benefit from thrumbolysis would be expected in patients 
*ilh u larger infarct size and lower ejection fraction. It was 
po%ulatcd that early thrombolytic therapy in patients with 
large areas of injured myocardium and severe left ventricular 
dysfunction mlghi improve survival. leading to a lower mean 
ejection fraction in treated patients compared with control 
patients; m the l.mer group. mean ejection fraction might 
conversely be increased by the death of high risk patients 
with Pou. ventricular function before the ejection fractwn 
measurement coslZ be determined (41). The validity of this 
hypothesis. however. depends on the lack of correlation 
between left vun~ricular ejection fraction and congestive 
heart failure. because il does not appear lhat thrombolytic 
therapy dramatically alters the incidence of death in patients 
who present wth congeslive hean failure or pulmonary 
edema. 
Other investigators (33.42) have questioned whether ejec- 
tion fraction should even be considered a valid end point in 
comparative trials. First. the measurement may be missing 
from as many at 3G% of patients enrolled in a trial becauseof 
dcath3 and unobtained or technically inadequate studies 
Table 4. lncidcnce af Congestive Heart Failure 
During Ho$piialization 
S,“d) Thrombolysis 




(331. Second. there is no correlalion belween preservalion of 
teft ventricular ejectiun fraction and time lo lreafmenl (33). 
Third. compensatory noninfarct zone hyperkinesia can 
maintain ejection frdctlon and mask lrealment benefil (43). 
Finally. lefi venbicular ejection fraction is significantly 
dcpendcni on ventricular loading condltmns that may change 
during tkc course of acute myocardial infarc!ion (42). 
Cnrdiogenic Shock 
Incidence. Cardiocenic shock remains the leadine cause 
of death after hnspitab~ion for acute mvocardial infarction 
(44). II has been &Eested that the incidence of cardiocenic 
shocb has dectined;n recent years, partly as a result of 
earlier hospilalization nnd lhc use of thrombolyGc agents 
144). Equally likely, however, are !he poasrbilitics lhar earty 
rcno~ts from lcrliarv care referral centers overestimated the 
incidence of cardioeenic shock comoarxl with admission 
rates in community ho&ah and that hypovolemic shock 
was underdiagnosed before central hemodynamic monitor- 
ing became possible (45). Data from the Muhicentcr Inves- 
tigation of Limitation of Infarct Size (MILIS) Srudy Group 
(461 obtained i.1 the 19705 demonstrated that 4.5% of patients 
with acute myucardial i&&on presented with cardiogenic 
shock (44) and lhal 7.1% developed cardiogenic shock after 
hospilal admission. In GISSI-I (I). a community hospilal 
trial, 2.5% of patienls prcsenled with cardiogenic shock and 
6”: developed shock during hospitalization. Mortalily ra::s 
are influenced hy the length of the observation period and 
have been reported (I.1 l-13,46) to range from 65% to 80%. 
Cardiogenic shock develops tihen >40% of the I& 
ventricle bcromes dysfunctional because of ischemia or 
infarcllon (47). Coronary care unit monitoring, pharmaco- 
logic treatment with vasopressor agents, vasodilators and 
inolropic agents and intraaortrc balloon counterpulsadon 
have not significantly altered mortality rates (48). More 
recent &tempts at. improving survival have involved reper- 
fusing ische.nic myocardium with thromholylic therapy. 
coronary angioplasly or coronary bypass graft surgery. 
Thrombolyfic therapy. Mathey et al. (49.50) were Ihe first 
to report successful reperfusion with intracoronary strep- 
tokinase and survival in three patients wirh cardiogenic 
shock. Forty-four patients were similarly treated in the 
Society for Cardiac Angiography’s intracoronary srreploki- 
nase registry (51). In 44 patients. the overall mortality rate 
was 66%. but patency was achieved in only 44%. ln the 19 
patients with successful rcperfuslon. the morrality rate was 
42%; in 25 palienls in whom reperfusion was unsuccessful, 
the mortality rate was 84%. The low patency rate in this 
subset conlrastr sharply with the overall patency rate of7l% 
in the registry. The low output state associated with card& 
genie shock may explain this finding. Recent work in an 
animal model of pulmonary embolism (521 emphasizes the 
importance of cardiac outpur on successful Ihrombolysis. 
Increasing a low cardiac output by 50% improved Ihe 
patency rate by SO%. 
Eqtnvaleni mor~ali!y rates 10 those reported in the Soci- 
ely for Cardiac Angiography’s intracoronzry slreptoktnase 
registry were found whh inaa,renaus streptokinasc in 
CXSSI-I (I) and the lnterrralionar trial (12.13) (Table 3). but 
the mortality rate did not differ from Ihat in the placebu- 
treated patienls in GISSI-I (I) or palients enrolled in the 
MILLS study (46). The MILIS study (46) additionally 
showed that infarcr extension occurred in 23% of patients 
wtlh cardiogenic shock compared wilh 7% of those without 
shock. The higher mortality rate in patients with cardiogenic 
shock treated wilh recombinant tissue-type plasminagen 
activator W-PA) in Ihe International trial (12.131 may reflect 
the higher reocclusion rates that can occur when intravenous 
heparin is not used with rt-PA (531. Furthermore. after 
thrombolytic therapy the incidence of cardicgenic shock 
during hospitalizaalion increases to 4% lo 6% (1,541, similar 
to the rate reported in the MlLIS trial (46). From available 
data. it is not cleal Ihal lhrombolytic therapy has reduced 
mortality due to cardiogenic shock. 
Mechanical revascnlarization in cardicgenic shock. At 
least I4 reports (48.5~67)* exist regarding the use of cmer- 
gcncy coronary angiopiasly in paiienis wilh cardiogcnic 
shock (Table 5). These show a reduction in mortality from 
the 65% 10 80% reported in previous studies (I,1 I-13,46) 10 
44%. Patency rates are 30 percentage points higher than 
those seen with intracoronary lhrombolytic therapy (SI). 
Successful rcperiusron in this meta-analysis was associated 
with a 30% mortality rate. whereas that after unsuccessful 
reperfusion was similar to that of hislorical control subjects. 
Interestingly. munality rales associated with sncccss or 
f&re of reperfusion are similar to those reported for the 
S-ciely for Cardiac Angiography’e intracoronary streptoki- 
nase registry (511. This finding lends further support to Ihe 
concepl that immediate reduction of a residual coronary 
stenosis by coronary angioplasly provides no additional 
benefit to restoration ofcoronary blood flow in patients with 
acute myocardkdl infarction 168-70). Patency rates after 
emergency angioplasty for acute myocardial infarction are 
somewhat lower than those reported for elective angioplasty 
in patients with angina pecioris (71) and success rates in 
patients wilh cardiogcnic shock are also lower than those 
noled in other patients with acute myocardial infarcuon (72). 
Emer~enc.v h!ppnss gru;r surgrr.v has been used infrre- 
quenlly in patients vhh cardiogenic sho:k (73-86) but with 
good results since I980 (Table 6). allhongh selection bias 
may have influenced outcome. Success is probably more 
dependen; on Ihe skill of (he surgical team than is the case 
with coronary angioplasly. where resulls tend to be more 
consistent among centers. Other benetils of coronary anpio. 
plasly compared with bypass graft surgery. besides lower 
COSI. are due to the speed and efficiency with which an;io- 
plaaly can be initiaied. Access to the cathererization labora. 
tory is easier and quicker than 10 the surgical suite. reperfu- 
sion can be achieved more rapidly and patients wiUl 
multiorgan hypoperfurion or advanced age may have lower 
“sk than with sur~$rery. The use of percutaneous support 
devices such as the inlraaortic balloon pum? (871. femoral- 
femoral bypass (881. coronary smus retroaclfurion (891 or 
the hemopump (90) potentially could maintain organ perfu- 
sion and limit organ darragc during the reperfusion anempt 
in the cat’leterization laboratory 
Conclusions 
Several conclusions can be drawn from existing data. 
First, early thrombolytlc therapy can reduce mfarct sue and 
preserve left ventricular ejection fraction. but I& vrntricular 
ejection fraction can improve without infarct size reduction 
Table 6. Coronary Artery Bypass GroA SurgUy for Cardiopnic 
Shock Comolicalina Acute ;\ivocardnl lnarcnon 
Johnson et aI, 176) 1977 
Ehrich et at. ~771 1971 
or earl? trearment if patcxy of the infarct-related artery is 
achieved (331 Second. prerervnlioa of left ventricular ejec- 
tion fraction should decrease mortality risk. but monalily 
reduction can uccui in the abwnce of improvement in left 
venrricular ejection fraction if patency of the infarct-related 
anrry 15 achievzd (41 t. Third. whereas thrombolytic lhenpy 
mw decrease the incidence vf heart fadure complicating 
acute myocardml infarction. it doe> sol clearly decrease 
mnrrality in patients who present with heart failure or 
cardiogenic Fhock. Finally. it is possible that mechanicai 
reperfusmn may signit?cantly decw.e morrJity in patients 
with cardmgenic s&k. but more dat;l are needed. 
Role of schievinl: coronary artery patency. It is likely thaw 
ali of the therapeutic benefit associated with reperfusior. 
therapy is the result of achievmg patency of ihe infaxt- 
related artery. Restoration of patency appears crucial for 
aurwval in patients with cardiigen~c shock. Because throm- 
bolytic therapy is associated uith low patency rates and do 
surwal beneRI in patients in Killip class IV. it is interesting 
to speculate whether tow patency rates or high reocclusion 
rates in patients in Killip classes II and III might be respon. 
sible for the discouraging survival rates seen with throm- 
bolytic therapy. Because up to 25% of palients eligible for 
reperfusion therapy are in Kiilip classes 11 to IV. it will be 
crit,cally important to determine in prospective trials 
whether higher patency rates associaied with coronary an- 
gioplasty or front-loaded rhrombolytic therapy I%) or lower 
reocclusion rates associated with combination thrombolytic 
therapy 192.93) cnn reduce the high mortality rates of pa- 
tients who present with left ventricular decompensarion 
despite standard thmmbolytic therapy. 
Recommendations. Until such data are forthcoming. ev- 
cry elfcrt should be made to maximlze patency of the 
infarct-reIdted artery in these patient% Adjunctive therapy 
wth aspirin (1) and intravenous hepann (53) should be 
mandatory. Likewise. wong cunsidcrarion should be given 
IO arlgmcnting coronary blued flow with inotropic or WSO- 
dilator agrntv ~521 or with rhe intrasonic balloon pump (87) 
IU improve reperfusion rates. Finally. mechanical rwasc~- 
laruatiun hhould be considered for patients wilh cardiogenic 
shock or con~cslive heart failure asrociated with hypolen- 
sion or iachccardia. 
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